What Reyvow Treats: Main Uses and Benefits

Reyvow is generally used to provide symptomatic relief for adults experiencing acute migraine headaches, including conditions characterized by episodes occurring with or without an aura. This medication is specifically applicable when the headache pain has reached a moderate or severe intensity. The primary therapeutic benefit contributes to easing the overall symptom load by addressing the headache severity, and may assist with managing intense pain when symptoms become noticeably overwhelming.

The medication is relevant for easing symptom clusters that often accompany the headache, including photophobia (light sensitivity), phonophobia (sound sensitivity), and nausea. It is applied across domains where additional symptomatic support is needed, especially during phases when symptoms become more noticeable.

“The medication is used to address pronounced symptoms during a disabling migraine attack, contributing to improved comfort during these periods of heightened symptoms.”

This medication is relevant in clinical settings that involve acute or unstable symptom patterns, and is applied across domains where short-term symptom management is appropriate. It is commonly used when supportive symptom management is appropriate, and is relevant for easing symptoms that interfere with daily comfort for adult patients.

---

Quick Fact: Symptomatic Relief

Reyvow is relevant for managing symptoms that interfere with daily comfort, such as the symptoms related to heightened physiological activity that often accompany the migraine.

Regulatory References

1. NIH MedlinePlus overview of Lasmiditan

Eligibility Profile for Reyvow (Lasmiditan)

The use of Reyvow is defined by specific population criteria established in regulatory labeling. The medicine is formally indicated for use in adults (18 years of age and older).

Eligibility Classification	Population Group	Regulatory Status
Absolute Contraindication	Patients with known hypersensitivity to lasmiditan or its excipients.	Explicitly prohibited.

Conditional and Restricted Use

The regulatory documentation specifies limitations for several groups:

• Age-Related: Safety and effectiveness have not been established in pediatric patients (under 18) or in geriatric patients (65 and older).
• Organ Function: Use is not recommended for patients with severe hepatic impairment (Child-Pugh Class C). No adjustment is required for any degree of renal impairment.
• Pregnancy/Lactation: Use is not recommended during pregnancy or while breastfeeding.
• Functional Restriction: A key constraint is that patients must not take Reyvow unless they can wait a minimum of eight hours before driving or operating machinery, due to the risk of impairment. The safety of treating more than four migraine attacks in a 30-day period has not been established.

Interactions with other medicines and products

Official regulatory documentation details the potential for pharmacodynamic (PD) reinforcement with several substance categories, resulting in interaction-related constraints and use cautions.

Pharmacodynamic and Transporter Interactions

Interacting Substance/Class	Official Interaction Description	Restriction/Constraint
Serotonergic Drugs (e.g., SSRIs, St. John's Wort)	Increased risk of Serotonin Syndrome	Use with caution is advised.
CNS Depressants (including alcohol)	Additive effect leading to enhanced CNS depression	Individuals must not drive or operate machinery for at least 8 hours after a dose.
P-gp Substrates (e.g., Digoxin)	Lasmiditan is an in vitro inhibitor of P-gp and BCRP.	Co-administration is not recommended for substrates where small concentration changes lead to serious toxicities.
Heart Rate Lowering Drugs (e.g., Propranolol)	Potential for additive heart rate lowering effect	Use with caution is advised.

Other Interaction Considerations

Lasmiditan is primarily metabolized by non-CYP enzymes, and co-administration with tested CYP enzyme substrates (CYP3A4, CYP1A2, CYP2C9) did not result in clinically meaningful changes to their systemic exposure. Regarding specific patient populations, the official label notes that the safety and exposure of the medicine are not known for individuals with severe hepatic impairment.

The mechanism of Lasmiditan is defined by its highly targeted action within the trigeminal system, utilizing a distinct pathway to modulate pain signaling at the molecular level. This approach is founded on three primary mechanistic domains.

Selective 5-HT1F Receptor Agonism

Lasmiditan is a selective agonist that binds specifically to the 5-HT1F receptor, which is expressed on nerve pathways integral to nociceptive transmission. This selective binding initiates a signal that hyperpolarizes the trigeminal neurons, resulting in the functional suppression of neuronal excitability. This molecular interaction is a defining feature of the drug's mechanism of action.

Inhibition of Pain-Mediator Release

The inhibitory action on the trigeminal neurons suppresses the release of pro-nociceptive neuropeptides, most notably Calcitonin Gene-Related Peptide (CGRP), from the nerve terminals. By modifying this molecular step, the mechanism helps limit the impact of excessive mediator activity, which dampens the transmission of nociceptive signals within the targeted pain pathway.

Non-Vasoconstrictive Mechanism and Dual Action

The molecule exhibits negligible affinity for the 5-HT1B receptor, ensuring that the mechanism exhibits negligible affinity for 5-HT1B receptors and the resultant generalized vasoconstriction. Furthermore, the molecule acts across both peripheral nerve endings and central pain processing centers (Trigeminal Nucleus Caudalis), modulating the nociceptive signaling dynamics within the peripheral and central nervous systems.

How Reyvow is Used

Reyvow is supplied as an oral tablet for the acute, intermittent use in managing migraine attacks. The medication is available in three distinct strengths: 50 mg, 100 mg, and 200 mg. The officially labeled dosing regimen involves administering a single tablet—at 50 mg, 100 mg, or 200 mg—taken as needed once a migraine attack has commenced. Common dosing includes an initial dose of 100 mg, with the possibility of adjustment to 200 mg for efficacy or 50 mg for tolerability.

Administration is structured around strict time constraints. No more than one dose of the medicine should be taken within any 24-hour period. For individuals who experience migraine recurrence within 24 hours after initial dosing, a second dose is possible, provided that a minimum interval of at least two hours has passed since the first dose. Furthermore, the safety of treating an average of more than four migraine attacks in a 30-day period has not been established.

The tablet may be administered with or without food but must always be swallowed whole; it should not be split, crushed, or chewed. A key procedural condition stipulates that patients must be advised to refrain from driving or operating machinery for at least 8 hours following the administration of each dose. Dose modifications are not necessary for older adults or for patients with mild to moderate kidney or liver impairment.

Research Evidence / Overview of Studies for Reyvow

Evidence for Use in Acute Migraine Attacks

The main research foundation for Reyvow consists of two large-scale, short-term randomized, controlled trials (RCTs), which focused on its evaluation when administered after a migraine attack has begun. These studies were applied in research contexts involving fluctuating or unstable symptoms, specifically for adult patients experiencing a migraine of moderate or severe intensity. The research examined outcomes related to physical discomfort, focusing on how symptoms changed in the observed populations over a short period. In these trials, patients receiving the investigational drug were compared against those receiving an inactive substance (placebo).

The studies monitored the proportion of patients who reported absence of pain—defined in the trials as the patient reporting no headache pain—at the two-hour mark after taking the medication. Another primary measure examined the proportion of patients reporting an absence of their most bothersome associated symptom (such as light sensitivity or nausea) at the same two-hour mark. Findings describe patterns observed in these studies, where measurements for both absence of pain and absence of the most bothersome symptom were statistically distinct from the inactive substance at the primary measurement time.

Study of Response Consistency and Durability

Studies also explored sustained responses beyond the initial two-hour assessment period, which is relevant in trials assessing short-term or episodic symptom patterns. The research highlights changes measured during the study period by tracking outcomes related to physical discomfort at later time points, up to 24 and 48 hours post-dose. This longer observation period tracked the durability of the initial reported outcome, particularly whether the reported absence of pain or the reported absence of the most bothersome symptom was sustained. Research also examined whether patients needed to use rescue medication to treat the same migraine episode at a later time. The research provides insight into short-term changes and studies contribute to the broader evidence landscape for short-term symptoms.

What is Still Uncertain and Research Gaps

One primary limitation is that initial regulatory review was primarily based on studies comparing the investigational drug against an inactive substance (placebo). Comparative evidence is lacking from large-scale, randomized trials directly comparing Reyvow to other common acute migraine therapies, such as triptans. Furthermore, clinical data for certain groups remain insufficient. Clinical data in pediatric populations (children and adolescents under 18 years) are still emerging. The available evidence for long-term outcomes for efficacy is also limited, as the longest studies were non-randomized, open-label designs.

Common questions about Reyvow (FAQ)

Q: What is the core difference between Reyvow and a triptan medication?

Reyvow is classified as a ditan, a distinct class of medicine from triptans. Official information describes it as selectively targeting the 5-HT1F receptor, which is different from the receptors targeted by triptans. This selective action is intended to avoid causing generalized vasoconstriction, which is the narrowing of blood vessels.

Q: Why is Reyvow classified as a Schedule V controlled substance?

According to the official product information, Reyvow is classified as a Schedule V controlled substance in the United States. This classification is due to documented evidence of the medicine's potential for abuse and physical dependence.

Q: How quickly does Reyvow typically start to work after a dose is taken?

Regulatory clinical studies measure the effectiveness of Reyvow primarily at the 2-hour mark after taking a dose, tracking the proportion of patients who achieve pain freedom or relief. The two-hour measurement mark is the time point used in key trials to determine if the medicine has been effective.

Q: How long does Reyvow remain in a person's system after it is taken?

The mean terminal half-life of lasmiditan (the active ingredient) is approximately 5 to 7 hours. Based on pharmacokinetics data, it takes roughly five half-lives, or about 25 to 35 hours, for the medicine to be nearly eliminated from the body.

Q: Can Reyvow be taken for migraine attacks that include an aura?

Official prescribing information states that Reyvow is indicated for the acute treatment of migraine attacks. This includes the treatment of migraine with or without an accompanying aura.

Q: What are the possible signs of Serotonin Syndrome when taking Reyvow?

Serotonin Syndrome is a serious condition that can result from a buildup of serotonin. Official documents list possible symptoms, including changes in mental status like agitation or hallucinations. Other signs include autonomic instability (such as a fast heart rate or unstable blood pressure) and neuromuscular signs like overactive reflexes.

Q: Is feeling "high" or euphoric a reported possible side effect of Reyvow?

Yes, official regulatory documents note that a 'euphoric mood' was reported as a less common adverse reaction in clinical trials. This effect was reported more frequently in patients who received Reyvow than those who received an inactive substance (placebo).

Q: What is the information available about taking Reyvow if I also use triptans?

Co-administration of Reyvow with triptan medications is generally cautioned. Both types of medicines affect serotonin pathways, and combining them could theoretically increase the risk of Serotonin Syndrome.

Q: Is Reyvow an option for people who have certain heart conditions or high blood pressure?

Unlike some other acute migraine treatments, Reyvow does not carry contraindications in its official labeling for pre-existing cardiovascular disease or uncontrolled high blood pressure. However, the medicine can cause transient changes, including a small, temporary increase in blood pressure and a temporary decrease in heart rate.

Q: What information is available regarding the safety of Reyvow for people over 65 years old (the geriatric population)?

Official information states that the safety and effectiveness of Reyvow have not been formally established in the geriatric population (patients age 65 and older). Clinical studies showed that older patients experienced a higher rate of dizziness compared to younger patients, even though dose adjustments are not typically required.

Q: What happens if a migraine attack returns after the initial dose of Reyvow?

Guidelines differ slightly between regions. The U.S. FDA-approved label describes the administration condition as limited to no more than one dose in a 24-hour period, noting that a second dose has not been shown to be effective for the same migraine attack. However, some international guidelines permit a second dose after a minimum of two hours if the migraine recurs within 24 hours.

Q: Is it possible for Reyvow to cause headaches to worsen or occur more frequently (Medication Overuse Headache)?

Yes, the official labeling warns that taking Reyvow too frequently may lead to a condition called Medication Overuse Headache (MOH). MOH is characterized by a marked increase in headache frequency. Regulatory safety documentation states that the safety of using Reyvow for more than four migraine attacks in a 30-day period has not been established.

How to Store and Dispose of Reyvow?

Reyvow (lasmiditan) tablets require storage at controlled room temperature, maintaining a required range of 68 F to 77 F (20 C to 25 C). Brief temperature excursions between 59 F to 86 F (15 C to 30 C) are permitted.

---

Child Safety and Handling

Due to the medicine's classification as a Schedule CV controlled substance, the product must be stored in a safe place to protect it from theft and must always be kept out of the reach of children, as specified in regulatory labeling.

---

Disposal of Unused Medicine

Official regulatory guidance requires that the disposal of any unused or expired Reyvow tablets must follow the specific State or local laws established for discarding controlled substances.